Product nameAnti-NLRP1 antibody [Nalpy1-4]
See all NLRP1 primary antibodies
DescriptionMouse monoclonal [Nalpy1-4] to NLRP1
Tested applicationsSuitable for: ICC, IP, IHC-Fr, IHC-P, WBmore details
Species reactivityReacts with: Human
Recombinant full length protein corresponding to Human NLRP1.
EpitopeRecognizes the pyrin domain (PYD) of human NLRP1.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.02% Sodium azide
Concentration information loading...
Purity>95% by SDS-PAGE
Purification notesPurified from concentrated hybridoma tissue culture supernatant.
Our Abpromise guarantee covers the use of ab16091 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration.|
|IHC-Fr||Use at an assay dependent concentration.|
|IHC-P||Use at an assay dependent concentration.|
|WB||1/1000. Predicted molecular weight: 171 kDa.|
FunctionAble to form cytoplasmic structures termed death effector filaments. Enhances APAF1 and cytochrome c-dependent activation of pro-caspase-9 and consecutive apoptosis. Stimulates apoptosis through activation of caspase-3. Involved in activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Binds ATP.
Tissue specificityWidely expressed. Isoform 1 and isoform 2 are expressed in peripheral blood leukocytes and chronic myelogenous leukemia cell line K-562, followed by thymus, spleen and heart. Also detected in brain, lung, placenta, small intestine, colon, kidney, liver, muscle, testis and epithelial cells. Absent from hematopoietic progenitor cells but expressed upon differentiation of cells into granulocytes and, to a lesser extent, monocytes. In peripheral blood cells, highest levels are found in T-lymphocytes, granulocytes and monocytes. Expression is significantly increased in bone marrow blast cells of some acute leukemia patients but not in solid tumors.
Involvement in diseaseGenetic variations in NLRP1 are associated with susceptibility to vitiligo (VTLG) [MIM:193200]. VTLG is a pigmentary disorder of the skin characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. It is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.
Genetic variations in NLRP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1 (VAMAS1) [MIM:606579]. VAMAS1 is an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.
Sequence similaritiesBelongs to the NLRP family.
Contains 1 CARD domain.
Contains 1 DAPIN domain.
Contains 6 LRR (leucine-rich) repeats.
Contains 1 NACHT domain.
Cellular localizationCytoplasm. Nucleus.
- Information by UniProt
- CARD 7 antibody
- CARD7 antibody
- Caspase recruitment domain protein 7 antibody
This product has been referenced in:
- Wei Y et al. NLRP1 Overexpression Is Correlated with the Tumorigenesis and Proliferation of Human Breast Tumor. Biomed Res Int 2017:4938473 (2017). Read more (PubMed: 29214170) »
- Zhang Y et al. Ginsenoside Rg1 protects against neuronal degeneration induced by chronic dexamethasone treatment by inhibiting NLRP-1 inflammasomes in mice. Int J Mol Med 40:1134-1142 (2017). Read more (PubMed: 28849171) »